Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

培美曲塞 医学 耐受性 内科学 安慰剂 临床终点 危险系数 肺癌 维持疗法 外科 随机对照试验 化疗 不利影响 胃肠病学 置信区间 顺铂 病理 替代医学
作者
Tudor–Eliade Ciuleanu,Thomas Brodowicz,Christoph Zielinski,Joo Hang Kim,Maciej Krzakowski,Eckart Laack,Yi‐Long Wu,Isabel Bover,Stephen Begbie,Valentina Tzekova,Branka Čučević,José Rodrigues Pereira,Sung Hyun Yang,Jayaprakash Madhavan,Katherine P. Sugarman,Patrick Peterson,William J. John,Kurt Krejcy,Chandra P. Belani
出处
期刊:The Lancet [Elsevier BV]
卷期号:374 (9699): 1432-1440 被引量:1117
标识
DOI:10.1016/s0140-6736(09)61497-5
摘要

Background Several studies have shown the efficacy, tolerability, and ease of administration of pemetrexed—an antifolate antineoplastic agent—in patients with advanced non-small-cell lung cancer. We assessed pemetrexed as maintenance therapy in patients with this disease. Methods This randomised double-blind study was undertaken in 83 centres in 20 countries. 663 patients with stage IIIB or IV disease who had not progressed on four cycles of platinum-based chemotherapy were randomly assigned (2:1 ratio) to receive pemetrexed (500 mg/m2, day 1) plus best supportive care (n=441) or placebo plus best supportive care (n=222) in 21-day cycles until disease progression. Treatment was randomised with the Simon and Pocock minimisation method. Patients and investigators were masked to treatment. All patients received vitamin B12, folic acid, and dexamethasone. The primary endpoint of progression-free survival and the secondary endpoint of overall survival were analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00102804. Findings All randomly assigned participants were analysed. Pemetrexed significantly improved progression-free survival (4·3 months [95% CI 4·1–4·7] vs 2·6 months [1·7–2·8]; hazard ratio [HR] 0·50, 95% CI 0·42–0·61, p<0·0001) and overall survival (13·4 months [11·9–15·9] vs 10·6 months [8·7–12·0]; HR 0·79, 0·65–0·95, p=0·012) compared with placebo. Treatment discontinuations due to drug-related toxic effects were higher in the pemetrexed group than in the placebo group (21 [5%] vs three [1%]). Drug-related grade three or higher toxic effects were higher with pemetrexed than with placebo (70 [16%] vs nine [4%]; p<0·0001), specifically fatigue (22 [5%] vs one [1%], p=0·001) and neutropenia (13 [3%] vs 0, p=0·006). No pemetrexed-related deaths occurred. Relatively fewer patients in the pemetrexed group than in the placebo group received systemic post-discontinuation therapy (227 [51%] vs 149 [67%]; p=0·0001). Interpretation Maintenance therapy with pemetrexed is well tolerated and offers improved progression-free and overall survival compared with placebo in patients with advanced non-small-cell lung cancer. Funding Eli Lilly.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zj发布了新的文献求助10
刚刚
酷波er的应助被Brave采纳,获得10
刚刚
江子川发布了新的文献求助10
1秒前
1秒前
777发布了新的文献求助10
1秒前
Jessica发布了新的文献求助10
3秒前
思源的应助被sasakiki采纳,获得10
3秒前
赘婿的应助被初见采纳,获得30
3秒前
3秒前
4秒前
内向晓旋完成签到,获得积分10
4秒前
Nefelibate完成签到,获得积分10
4秒前
Hello的应助被魏同心采纳,获得10
5秒前
5秒前
6秒前
江子川发布了新的文献求助10
6秒前
江子川发布了新的文献求助10
7秒前
7秒前
江子川发布了新的文献求助10
7秒前
江子川发布了新的文献求助10
7秒前
江子川发布了新的文献求助10
7秒前
Lucas的应助被内向晓旋采纳,获得10
7秒前
8秒前
8秒前
奥利奥发布了新的文献求助10
8秒前
GIN完成签到,获得积分10
9秒前
爆米花的应助被小粒橙采纳,获得10
9秒前
恬恬完成签到 ,获得积分10
10秒前
江子川发布了新的文献求助10
10秒前
小马完成签到 ,获得积分10
10秒前
江子川发布了新的文献求助10
10秒前
江子川发布了新的文献求助10
11秒前
江子川发布了新的文献求助10
11秒前
11秒前
执着的忆雪完成签到 ,获得积分10
11秒前
11秒前
天天快乐的应助被kyyy采纳,获得10
11秒前
11秒前
Akim的应助被小熊维尼采纳,获得10
12秒前
田青君完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192250
求助须知:如何正确求助?哪些是违规求助? 9578881
关于积分的说明 21862513
捐赠科研通 7791814
什么是DOI,文献DOI怎么找? 3436868
关于科研通互助平台的介绍 2560584
邀请新用户注册赠送积分活动 2483698